Clinical indications for when to use CADET® BRAF and CADET® BRAF-PLUS
Clinical cases presenting with hematuria, stranguria, and/or urinary incontinence with diagnostic imaging evidence of a mass in the bladder. |
Early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass. |
Confirmation of the TCC/UC diagnosis of a bladder mass from a stained cytology slide following ultrasonography and cytological examination of a fine-needle aspirate from tumor-bearing cells. |
Early detection in high-risk dog breeds such as terriers, Shetland and Australian sheep dogs, cattle dogs, beagles, and border collies that are 6 years and older. |
During chemotherapy to monitor treatment success by decreased levels of BRAF mutation detection, or to monitor cancer relapse by recurrence of BRAF mutation tumor-bearing cells. |